Cargando…
Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition
Anti-neoplastic agents for cancer treatment utilize many different mechanisms of action and, when combined, can result in potent inhibition of cancer growth. Combination therapies can result in long-term, durable remission or even cure; however, too many times, these anti-neoplastic agents lose thei...
Autores principales: | Singh, Sunanda, Gomez, Hector J., Thakkar, Shreya, Singh, Samara P., Parihar, Ashutosh S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002572/ https://www.ncbi.nlm.nih.gov/pubmed/36902166 http://dx.doi.org/10.3390/ijms24054722 |
Ejemplares similares
-
Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas
por: Liu, Fang, et al.
Publicado: (2013) -
A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers
por: Singh, Sunanda, et al.
Publicado: (2022) -
Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
por: Mumin, Nuramalina H., et al.
Publicado: (2019) -
Suppression of Breast Cancer Cell Proliferation by Selective Single-Domain Antibody for Intracellular STAT3
por: Singh, Sunanda, et al.
Publicado: (2018) -
Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma
por: Hu, Beiyuan, et al.
Publicado: (2022)